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Macrocyclic peptides have promising therapeutic potential but the
scaling up of their chemical synthesis is challenging. The cyano-
bactin macrocyclase PatGmac is an eﬃcient tool for production but
is limited to substrates containing 6–11 amino acids and at least
one thiazoline or proline. Here we report a new cyanobactin
macrocyclase that can cyclize longer peptide substrates and those
not containing proline/thiazoline and thus allows exploring a wider
chemical diversity.
Macrocyclic peptides show great promise as therapeutics because
they have an increased target binding aﬃnity and selectivity, aremore
stable against proteolytic enzymes and often have higher membrane
permeability when compared to their linear counterparts.1,2 These
scaﬀolds can modulate therapeutic targets that involve extended
binding surfaces such as protein–protein interactions3 known to
be challenging for small molecule drugs.4–6 However, macrocyclic
peptides are under-exploited due to challenges in their chemical
production on a large scale. Several chemical ring closing strate-
gies have been proposed including metathesis, click chemistry,
metal-templated chelation and the use of auxiliaries but all have
variable success rates and inherent limitations.7
Biochemical approaches include sortase-mediated ligation,8
split-intein circular ligation of peptides and proteins9,10 and the
use ofmacrocyclases from the biosynthetic pathways of ribosomally
synthesized and post-translationally modified peptides (RiPPs).11
The former approach incorporates a pentapeptide in the product,
while the second cannot be used for substrates containing more
than one non-natural amino acid.12 Several macrocyclases from
RiPP classes have been identified including butelase-1,13
GmPOPB,14 and PCY115 which are involved in the formation
of cyclotides, a-amanitin, and segetalin A respectively. The
diﬃculty in the recombinant production or the requirement
for long recognition sequences has impeded the wider applica-
tion of these enzymes. Other RiPP macrocyclases are derived
from azole-containing cyclic peptide cyanobactin pathways.
PatGmac from the patellamide pathway has so far been the
only structurally characterized cyanobactin macrocyclase.16,17 The
enzyme is tolerant to changes in the substrate sequence18 and has
been successfully used to produce a library of macrocyclic peptides
in vitro.19 PatGmac is a subtilisin-like protease that recognizes a three-
residue signal at the C-terminus of the substrate, cleaves it oﬀ and
forms an acyl complex with the residue at the P1 position. The
enzyme accepts the substrate in a bent conformation in which the
N-terminal amino group is in close proximity to the acyl complex
(Fig. 1).20 This conformation is facilitated by the conformational
properties of the Pro or thiazoline residues at the P1 position. This
may explain why, for cyanobactins, a Pro or a heterocyclized Cys
residue is always found at the P1 position.21
However, PatGmac can cyclize only substrates containing
6–11 amino acids and it requires that the substrate have Pro or
thiazoline before the recognition signal which is incorporated in
the cyclic product.16 Here we report a new cyanobactin macro-
cyclase that can cyclize longer substrates and accepts (Cys)- and
(Ser)-pseudoprolines at position P1. Oxazolidine-based pseudo-
proline rings can adopt an s-cis amide conformation analogous
to Pro/thiazoline residues.
Genome mining studies identified a cryptic cyanobactin gene
cluster in the draft genome of Oscillatoria sp. PCC 6506.22,23
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The 12.9 kb cryptic osc gene cluster encodes two precursor
peptides and six biosynthetic enzymes (Fig. 2 and Table S1,
ESI†). Analysis of the strain’s methanolic extracts by LC-ITMS/
QTOF revealed that OscE2 encodes a 17-mer prenylated cyclic
peptide in which Cys residues are heterocyclized and oxidised
to thiazoles (Fig. S1, ESI†). The monoisotopic mass of the
protonated putative cyanobactin was 1896.7287 m/z (calc. for
C87H110N21O22S3 m/z 1896.72909, D 0.2 ppm). The presence of an
isoprenoid unit was verified by the neutral loss of 68 Da in the MS
and MS2 spectra. The position of prenylation (on Trp between Thr
and Gly) was determined based on the presence of the product ions
9–12 in the QTOF MS2 spectrum (Table S2, ESI†). The second
precursor peptide OscE1 encodes a 25-mer cyclic peptide containing
three thiazoles and no prenylated residue. A mass corresponding
to the double protonated molecule m/z 1275.9993 (calc. for
C113H149N29O34S3 m/z 1275.99864, D 0.5 ppm) was detected
and the fragmentation is shown in Table S2 (ESI†).
Oscillatoria sp. PCC 6506 cells were labelled with 15N and 34S
in order to further confirm the structures of the putative cyano-
bactins (Fig. S2 and S3, ESI†). 15N-labelled protonated cyano-
bactins A and B show an increase of 21 and 29 mass units,
respectively, equating to the same number of nitrogen atoms in
these molecules (Fig. S2, ESI†). Similarly 34S-labelled proto-
nated cyanobactins A and B show an increase of 6 mass units
equating to 3 sulphur atoms in both molecules (Fig. S3, ESI†).
Altogether all the results are in full agreement with the struc-
tures predicted from the gene cluster. We named these cyano-
bactins oscillacyclamides A and B respectively (Fig. 2).
OscGmac was expressed in E. coli and purified (Fig. S4 and S5,
ESI†). A series of 19 linear peptide substrates (Table 1) was used
to test the enzyme substrate specificity. Some of these substrates
were made as part of our ongoing eﬀorts to chemo-enzymatically
produce the anti-HIV depsipeptide homophymine A (Fig. S53,
ESI†) and to test the substrate specificity of diﬀerent cyanobactin
macrocyclases. The peptide substrates were designed to include
the PatGmac recognition signal (Ala-Tyr-Asp) or the PirGmac (from
the piricyclamide pathway24) signal (Phe-Ala-Gly-Asp) at the
C-terminus. The recognition signal of PatGmac resembles those
present in OscE1 and OscE2 for OscGmac (Ser-Phe/Tyr-Asp) and
follows the order of a small amino acid, an aromatic residue and
an acidic residue. The crystal structure of PatGmac
16 showed that the
substrate P10 alanine Ca and side chain make only a few hydro-
phobic interactions with the enzyme and sits in a cavity that appears
to be large enough for bulkier residues. The natural recognition
signal of the homologous macrocyclase, PirGmac, contains a bulkier
residue (Phe) in P10. In our hands, PatGmac did not process any of
the substrates containing the recognition signal of its homologue
PirGmac. In comparison, OscGmac shows higher substrate promiscuity
and could process substrates containing both of these recognition
signals (Table 1). Cyclic products of the enzymatic reactions contain
6–30 amino acids and each of the 20 canonical amino acids was
incorporated at least once into the products.
The enzyme tolerability for substrates containing D-amino acids
in positions P2, P6 and P7 was investigated (substrates 4–9, 11 and
12; Table 1). A maximum of three D-amino acids per substrate was
incorporated that are neutral, small hydrophobic, basic or acidic.
Remarkably, all substrates except those containing D-amino acids
in the P2 position were processed by OscGmac (Table 1). This may
be due to the fact that the P2 position is close to position P1
which is conformationally critical to macrocyclisation. Having a
D-stereocentre in position P2, thus, may prevent the substrate
adopting the bent conformation.
In eﬀect, the prerequisite by PatGmac for having Pro or thiazo-
line in position P1 limits the diversity of the cyclic peptides that
can be generated. In order to overcome this limitation, sequences
containing (Cys)- and (Ser)-pseudoprolines at P1 were tested
(sequences 2, 17 and 18; Table 1). None of these sequences were
processed by PatGmac. However, OscGmac was able to macrocyclise
the des(dimethyl) pseudoproline-containing peptides (sequences
2 and 18; Table 1) as observed using LC-MS analyses (Fig. S8 and
S9 and S49 and S50, ESI†). Peptide 17, which contains a dimethyl-
pseudoproline known to be the preferred substrate for facile
reversion to serine,25–27 was not processed most probably for
steric reasons.
We tried to estimate the catalytic rate of OscGmac but
obtaining reliable kinetics is complicated owing to the fact that
OscGmac is present at420 mol%
28 and that the catalytic rate of
the enzyme is substrate dependent. We are working on under-
standing the factors aﬀecting the rate of cyclisation using a
mixed experimental and theoretical approach.20
We aligned the sequence of OscGmac with those of 7 other cyano-
bactin macrocyclases listed in Table S3 (ESI†) (Fig. S54, ESI†)
and created a Phyre2 model29 for OscGmac using the crystal
structure of PatGmac (PDB 4AKS) as a template (Fig. S55, ESI†).
Fig. 1 A cartoon showing the substrate binding with PatGmac and the
steps of enzyme-mediated cyclization. (A) Binding of the enzyme with the
recognition signal. (B) Cleavage of the recognition signal and formation of
an acyl complex with the residue at position P1. (C) Formation of an amide
bond and cyclization of the peptide.
Fig. 2 The osc gene clusters and sequences of OscE1 and OscE2 precursor
peptides. Structures of oscillacyclamide A (left) and oscillacyclamide B (right)
are shown. Core sequences are highlighted in yellow.
Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
Se
pt
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
6/
11
/2
01
7 
12
:0
0:
20
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
10658 | Chem. Commun., 2017, 53, 10656--10659 This journal is©The Royal Society of Chemistry 2017
Our alignment shows that the key residues in PatGmac are highly
conserved in all of these enzymes. These residues according to the
PatGmac sequence are as follows: (1) the Asp57, His127, and Ser292
that form the catalytic triad; (2) the Lys103, Lys107 and Phe256 that
make interactions with the Ala-Tyr-Asp recognition signal; (3) the
Asn226 that stabilizes the tetrahedral intermediate and (4) the
Cys194, Cys233, Cys332 and Cys343 that form two critical disulfide
bridges. PatGmac’s Cys194–Cys233 disulfide bond bridges two loops
resulting in the protrusion of three bulky residues; Met169, Phe193
and Arg195 close to the active site.16 These residues prevent the
binding of substrates that adopt an extended conformation. Inter-
estingly, the corresponding residues in OscGmac (Ile183, Ala207,
Cys209) are smaller in size and thismay allow extra space for longer
substrates to bind (Fig. S54 and S55, ESI†).
In order to test this hypothesis, we generated PatGmac mutants
in which the native bulky residues were replaced with those that are
smaller from OscGmac. Mutants include the single M169I, F193A
and R195C; the double M169I F193A, M169I R195C and F193A
R195C and the triple M169I F193A R195C. All mutants were
expressed in E. coli and purified (Fig. S56, ESI†) and their activities
were compared with that of PatGmac. Strikingly, the mutant M169I
processed substrate 1 (Table 1) which could not be processed with
PatGmac or any of its other mutants (Fig. S57, ESI†). In addition, we
observed that reactions of the mutants M169I F193A and M169I
F193A R195C with substrate 15 (Table 1) resulted in cyclisation of
most of the linear precursor peptide, compared to PatGmac, which
could cyclize only part of it over the same time frame (Fig. S58–S60,
ESI†). These results showed that these mutations resulted in
slightly altered activity. However, none of these mutants were able
to process the 29mer (substrate 14; Table 1) most probably because
of the different recognition signal in this substrate.
The above results show that the cyanobactin macrocyclase
OscGmac can process substrates containing Cys- and Ser-
pseudoprolines instead of Pro and thiazoline at position P1.
Table 1 Sequences of the synthetic peptide substrates used for testing the functionality and promiscuity of OscGmac and the resultant cyclic products
Peptide Sequence Product
Cyclization
with OscGmac
Figure
(ESI)
1 H-Asn-Glu-Phe-Met-Gln-Thr-Gly-Ser-Tyr-
Ser-Gly-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Asn-Glu-Phe-Met-Gln-Thr-Gly-Ser-Tyr-
Ser-Gly-Pro-]
Yes S6 and S7
2 H-Val-Gly-Ala-Gly-Ile-Gly-Phe-Ser(cPro)-
Ala-Tyr-Asp-Gly-OH
Cyclo-[Val-Gly-Ala-Gly-Ile-Gly-Phe-Ser(cPro)-] Yes S8 and S9
3 Fmoc-Ala(Amino)-Ser-Lys-Leu-Gln-Ile-
Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-Ser-Lys-Leu-Gln-Ile-
Asp-Pro-]
Yes S10–S12
4 Fmoc-Ala(Amino)-Ser-Lys-Leu-Gln-Ile-
D-Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-Ser-Lys-Leu-Gln-Ile-D-
Asp-Pro-]
No S13 and S14
5 Fmoc-Ala(Amino)-Ser-D-Lys-Leu-Gln-Ile-
Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-Ser-D-Lys-Leu-Gln-Ile-
Asp-Pro-]
Yes S15–S18
6 Fmoc-Ala(Amino)-D-Ser-Lys-Leu-Gln-Ile-
Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-D-Ser-Lys-Leu-Gln-Ile-
Asp-Pro-]
Yes S19–S22
7 Fmoc-Ala(Amino)-Ser-D-Lys-Leu-Gln-Ile-
D-Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-Ser-D-Lys-Leu-Gln-Ile-
D-Asp-Pro-]
No S23 and S24
8 Fmoc-Ala(Amino)-D-Ser-Lys-Leu-Gln-Ile-
D-Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-D-Ser-Lys-Leu-Gln-Ile-
D-Asp-Pro-]
No S25 and S26
9 Fmoc-Ala(Amino)-D-Ser-D-Lys-Leu-Gln-
Ile-Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-D-Ser-D-Lys-Leu-Gln-Ile-
Asp-Pro-]
Yes S27–S30
10 Fmoc-Ala(Amino)-Ser-Lys-Leu-Gln-Ile-
Ala-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-Ser-Lys-Leu-Gln-Ile-
Asp-Pro-]
Yes S31–S34
11 Fmoc-Ala(Amino)-Ser-Lys-Leu-Gln-Ile-
D-Ala-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-Ser-Lys-Leu-Gln-Ile-
D-Ala-Pro-]
No S35 and S36
12 Fmoc-Ala(Amino)-D-Ser-D-Lys-Leu-Gln-
Ile-D-Asp-Pro-Ala-Tyr-Asp-Gly-OH
Cyclo-[Dpr(Fmoc)-D-Ser-D-Lys-Leu-Gln-Ile-
D-Asp-Pro-]
No S37 and S38
13 H-His-Gln-Trp-Gly-Trp-Leu-Val-Gly-Gly-
Thr-Asp-Pro-Phe-Ala-Gly-Asp-OH
Cyclo-[His-Gln-Trp-Gly-Trp-Leu-Val-Gly-
Gly-Thr-Asp-Pro-]
Yes S39 and S40
14 H-Asp-Trp-Gly-Thr-Phe-Cys-Val-Gln-Glu-
Asp-Gly-Glu-Gly-Asn-Cys-Lys-Glu-Trp-Tyr-
Glu-Leu-Pro-Phe-Ala-Gly-Asp-Asp-Ala-
Glu-OH
Cyclo-[Asp-Trp-Gly-Thr-Phe-Cys-Val-Gln-
Glu-Asp-Gly-Glu-Gly-Asn-Cys-Lys-Glu-Trp-
Tyr-Glu-Leu-Pro-] (disulfide bond)
Yes S41 and S42
15 H-Val-Gly-Ala-Gly-Ile-Gly-Phe-Pro-Ala-Tyr-
Asp-OH
Cyclo-[Val-Gly-Ala-Gly-Ile-Gly-Phe-Pro-] Yes S43 and S44
16 H-Val-Ala-Gly-Ile-Gly-Phe-Pro-Ala-Tyr-
Asp-OH
Cyclo-[Val-Ala-Gly-Ile-Gly-Phe-Pro-] Yes S45 and S46
17 H-Val-Gly-Ala-Gly-Ile-Gly-Phe-
Ser(cMe,MePro)-Ala-Tyr-Asp-Gly-OH
Cyclo-[Val-Gly-Ala-Gly-Ile-Gly-Phe-
Ser(cMe,MePro)-]
No S47 and S48
18 H-Val-Ala-Gly-Ile-Gly-Phe-Cys(cPro)-Ala-
Tyr-Asp-OH
Cyclo-[Val-Ala-Gly-Ile-Gly-Phe-Cys(cPro)-] Yes S49 and S50
19 H-Gly-Val-Cys-Gly-Glu-Thr-Cys-Val-
Gly-Gly-Thr-Cys-Asn-Thr-Pro-Gly-Cys-Thr-
Cys-Ser-Trp-Pro-Val-Cys-Thr-Arg-Asn-
Gly-Leu-Pro-Ala-Tyr-Asp-Gly-Glu-Leu-Glu-
His-His-His-His-His-His-OH (two
disulfide bonds)
Cyclo-[Gly-Val-Cys-Gly-Glu-Thr-Cys-Val-
Gly-Gly-Thr-Cys-Asn-Thr-Pro-Gly-Cys-Thr-
Cys-Ser-Trp-Pro-Val-Cys-Thr-Arg-Asn-Gly-
Leu-Pro-] (two disulfide bonds)
Yes S51 and S52
Dpr = 2,3-diaminopropionic acid.
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OscGmac has a wider substrate tolerance, including D-amino acids,
can process longer peptide substrates and has less stringent recogni-
tion determinants when compared to PatGmac. We hypothesized
that the residues Ile183, Ala207, and Cys209 are responsible for the
altered tolerance to certain substrates and showed that mutations of
these residues in PatGmac resulted in altered activity and in a specific
instance amutant processed a substrate that could not be processed
by PatGmac. OscGmac, thus, is a very useful biotechnological tool to
make modified cyclic peptides.
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